<DOC>
	<DOCNO>NCT00548912</DOCNO>
	<brief_summary>The hypothesis trial ass effect spironolactone heart size mass</brief_summary>
	<brief_title>Left Ventricular Hypertrophy Spironolactone End Stage Renal Disease</brief_title>
	<detailed_description>Dialysis patient significant morbidity mortality associate leave ventricular hypertrophy cardiac failure . Aldosterone may important role development myocardial hypertrophy remodeling . Animal study demonstrate beneficial effect aldosterone antagonists myocardial hypertrophy , human study show significant survival benefit non-dialysis population congestive heart failure . This study evaluate effect spironolactone ( aldosterone receptor antagonist ) cardiac hypertrophy end-stage renal disease population .</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Hypertrophy , Left Ventricular</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<criteria>hemodialysis patient non compliance hyperkalemia pregnancy expect survival less 9 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>Kidney Failure , Chronic</keyword>
	<keyword>Hemodialysis</keyword>
	<keyword>Spironolactone</keyword>
</DOC>